my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
19-03-2012: Agilent Technologies Inc. announced that it has entered into a Cooperative Research and Development Agreement with the U.S. Food and Drug Administration to develop new tools to detect and analyze pathogens in food. The joint R&D effort will also seek to improve DNA-based tools for confirming that seafood is correctly labeled.
The goal of the first part of the project is to develop a novel assay panel to identify subtypes of salmonella in food. When outbreaks occur, knowing the subtype can help officials quickly identify the source of the pathogen and hopefully limit the number of victims. The research will focus on using mass spectrometry-based genotyping to quickly identify salmonella subtypes.
The second part of the agreement – to be carried out in collaboration with both the FDA and the Campden BRI laboratory in the United Kingdom – aims to update Agilent’s lab-on-a-chip method of DNA analysis to identify fish species. Agilent’s analytical technique can identify species even after the fish has been processed, which generally removes identifying features such as the head, tail and skin. The technology is based on the Agilent Bioanalyzer, using restriction fragment length polymorphism. The goal is to make this technology fast, inexpensive and simple enough that many kinds of laboratories can use it on a routine basis. This type of test could detect such things as intentional mislabeling to avoid tariffs and import restrictions or economic fraud where a less expensive species of fish is sold as a more costly species.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Agilent Technologies Inc. opened a new Customer Applications and Training Center in South Korea, showcasing its latest bio-analytical instruments. The company’s goal is to collaborate with customers to develop new applications and methodologies for research in the agriculture, environment a ... more
Agilent Technologies Secures Patent for CGH Assays
Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research. The U.S. patent (No. 8,232,055) has claims for measuring copy number change ... more
Agilent to Acquire Dako for $2.2 Billion
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In ... more
Half a Century of Chromatography with Agilent and Predecessors
Twsett originated the chromatography with his work about the separation of chlorophyll in 1903. For some time it was relatively quite around this new technology. Exceptions were the workings of Kuhn and Lederer (1931) as well as of Hesse (1936 and 1942). A break through succeeded to E. Crem ... more
Agilent Technologies Sales & Services GmbH & Co. KG
Agilent T. is a global diversified technology company that serves markets that include communications, electronics and life sciences. more
Epigenomics submits the fourth module to the FDA for Epi proColon
Epigenomics AG announced that it has submitted the fourth and final module of its Premarket Approval (PMA) to the United States Food & Drug Administration (FDA) for its blood-based Epi proColon® test for the detection of colorectal cancer in December 2012 as previously indicated, thereby co ... more
FDA Approves Genzyme’s AUBAGIO (teriflunomide), a Treatment for Relapsing Multiple Sclerosis
Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). AUBAGIO has shown significant efficacy across key measures ... more
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), the first new granulocyte colony-stimulating factor (G-CSF) to be approved in the United States in more than 10 years. Tbo-filgrastim is ... more
U. S. Food and Drug Administration (FDA)
FDA is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. FDA is also responsible for advancing the public hea ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
